Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Investing on MSN2d
Axsome Therapeutics stock rises on patent litigation settlementAxsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
"Migraine attacks strike without warning, and disrupt the lives of an estimated more than 39 million patients in the U.S. alone," Herriot Tabuteau, M.D., CEO of Axsome Therapeutics, said in a ...
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...
On a conference call, Axsome chief executive Herriot Tabuteau said the company was pleased with the approved label for Auvelity, particularly its broad indication in MDD and wording that indicates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback